International Clinical Trial: Combination Therapy With Tazemetostat in Relapsed and Refractory Peripheral T-cell Lymphoma

Geneva, Oct. 21 -- International Clinical Trials Registry received information related to the study (NCT07209163) titled 'Combination Therapy With Tazemetostat in Relapsed and Refractory Peripheral T-cell Lymphoma' on Sept. 30.

Study Type: Interventional

Study Design: Allocation: Non-Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: None (Open Label).

Primary Sponsor: Ruijin Hospital

Condition: Peripheral T Cell Lymphoma

Intervention: Drug: Tazemetostat Drug: Linperlisib

Recruitment Status: Not recruiting

Phase: Phase 1/Phase 2

Date of First Enrollment: October 2025

Target Sample Size: 48

To know more, visit https://clinicaltrials.gov/study/NCT07209163

Published by HT Digital Conte...